Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2012 (2012), Article ID 761364, 12 pages
http://dx.doi.org/10.1155/2012/761364
Review Article

Ductal Carcinoma In Situ of the Breast: A Surgical Perspective

Department of Surgical Oncology, Rehabilitation Associates of Northern Illinois, Rockford, IL 61111, USA

Received 13 January 2012; Revised 9 April 2012; Accepted 7 May 2012

Academic Editor: Bernando Bonanni

Copyright © 2012 Mohammed Badruddoja. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Shampo and R. A. Kyle, “Pioneers of mammography—Warren and Egan,” Mayo Clinic Proceedings, vol. 72, no. 1, article 32, 1997. View at Google Scholar · View at Scopus
  2. D. Rosner, R. N. Bedwani, and J. Vana, “Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons,” Annals of Surgery, vol. 192, no. 3, pp. 139–147, 1980. View at Google Scholar · View at Scopus
  3. L. A. Brinton, M. E. Sherman, J. D. Carreon, and W. F. Anderson, “Recent trends in breast cancer among younger women in the United States,” Journal of the National Cancer Institute, vol. 100, no. 22, pp. 1643–1648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. V. L. Ernster, R. Ballard-Barbash, W. E. Barlow et al., “Detection of ductal carcinoma in situ in women undergoing screening mammography,” Journal of the National Cancer Institute, vol. 94, no. 20, pp. 1546–1554, 2002. View at Google Scholar · View at Scopus
  5. D. S. May, N. C. Lee, L. C. Richardson, A. G. Giustozzi, and J. K. Bobo, “Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States),” Cancer Causes and Control, vol. 11, no. 8, pp. 697–705, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. I. Li, J. R. Daling, and K. E. Malone, “Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 4, pp. 1008–1011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. V. L. Ernster, J. Barclay, K. Kerlikowske, D. Grady, and I. C. Henderson, “Incidence of and treatment for ductal carcinoma in situ of the breast,” JAMA, vol. 275, no. 12, pp. 913–918, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Horner, L. Rice, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2006, National Cancer Institute, Bethesda, Md, USA, 2009.
  10. B. A. Virnig, T. M. Tuttle, T. Shamliyan, and R. L. Kane, “Ductal carcinoma in Situ of the breast: a systematic review of incidence, treatment, and outcomes,” Journal of the National Cancer Institute, vol. 102, no. 3, pp. 170–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Tabar, G. Fagerberg, H.-H. Chen et al., “Efficacy of breast cancer screening by age: new results from the Swedish two-county trial,” Cancer, vol. 75, no. 10, pp. 2507–2517, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Tabár, B. Vitak, H. H. Chen et al., “The Swedish two-county trial twenty years later: updated mortality results and new insights from long-term follow-up,” Radiologic Clinics of North America, vol. 38, no. 4, pp. 625–651, 2000. View at Google Scholar · View at Scopus
  13. N. G. Coburn, M. A. Chung, J. Fulton, and B. Cady, “Decreased breast cancer tumor size, stage, and mortality in Rhode Island: an example of a well-screened population,” Cancer Control, vol. 11, no. 4, pp. 222–230, 2004. View at Google Scholar · View at Scopus
  14. J. Fracheboud, S. J. Otto, J. A. M. M. Van Dijck, M. J. M. Broeders, A. L. M. Verbeek, and H. J. De Koning, “Decreased rates of advanced breast cancer due to mammography screening in The Netherlands,” British Journal of Cancer, vol. 91, no. 5, pp. 861–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. W. F. Anderson, K. C. Chu, and S. S. Devesa, “Distinct incidence patterns among in situ and invasive breast carcinomas, with possible etiologic implications,” Breast Cancer Research and Treatment, vol. 88, no. 2, pp. 149–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Y. Chen, L. M. Sun, and B. O. Anderson, “Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S,” Cancer, vol. 107, no. 7, pp. 1448–1458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. L. Weaver, P. M. Vacek, J. M. Skelly, and B. M. Geller, “Predicting biopsy outcome after mammography: what is the likelihood the patient has invasive or in situ breast cancer?” Annals of Surgical Oncology, vol. 12, no. 8, pp. 660–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Tavassoli, “Ductal intraepithelial neoplasia of the breast,” Virchows Archiv, vol. 438, no. 3, pp. 221–227, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Kricker, C. Goumas, and B. Armstrong, “Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology,” British Journal of Cancer, vol. 90, no. 7, pp. 1382–1385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. E. B. Claus, M. Stowe, and D. Carter, “Breast carcinoma in situ: risk factors and screening patterns,” Journal of the National Cancer Institute, vol. 93, no. 23, pp. 1811–1817, 2001. View at Google Scholar · View at Scopus
  21. G. K. Reeves, V. Beral, J. Green, T. Gathani, and D. Bull, “Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis,” The Lancet Oncology, vol. 7, no. 11, pp. 910–918, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Gapstur, M. Morrow, and T. A. Sellers, “Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study,” JAMA, vol. 281, no. 22, pp. 2091–2141, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. E. B. Claus, M. Stowe, and D. Carter, “Oral contraceptives and the risk of ductal breast carcinoma in situ,” Breast Cancer Research and Treatment, vol. 81, no. 2, pp. 129–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Kerlikowske, J. Barclay, D. Grady, E. A. Sickles, and V. Ernster, “Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer,” Journal of the National Cancer Institute, vol. 89, no. 1, pp. 77–82, 1997. View at Google Scholar · View at Scopus
  25. J. Wohlfahrt, F. Rank, N. Kroman, and M. Melbye, “A comparison of reproductive risk factors for CIS lesions and invasive breast cancer,” International Journal of Cancer, vol. 108, no. 5, pp. 750–753, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. National and Medical Research Council, Hormone Replacement Therapy: A Summary of the Evidence for General Practitioners and oOther Health Professionals, National Health and Medical Council, Canberra, Australia, 2005.
  27. J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial,” JAMA, vol. 288, no. 3, pp. 321–333, 2002. View at Google Scholar · View at Scopus
  28. G. L. Anderson, R. T. Chlebowski, J. E. Rossouw et al., “Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin,” Maturitas, vol. 55, no. 2, pp. 103–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. M. L. Stefanick, G. L. Anderson, K. L. Margolis et al., “Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy,” JAMA, vol. 295, no. 14, pp. 1647–1657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Y. Chen, J. E. Manson, S. E. Hankinson et al., “Unopposed estrogen therapy and the risk of invasive breast cancer,” Archives of Internal Medicine, vol. 166, no. 9, pp. 1027–1032, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Tamimi, S. E. Hankinson, W. Y. Chen, B. Rosner, and G. A. Colditz, “Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women,” Archives of Internal Medicine, vol. 166, no. 14, pp. 1483–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. S. R. Cummings, B. Ettinger, P. D. Delmas et al., “The effects of tibolone in older postmenopausal women,” The New England Journal of Medicine, vol. 359, no. 7, pp. 697–708, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. Australian Bureau of Statistics, National Health Survey, Australia (2004-2005), Australian Bureau of Statistics, Canberra, Australia, 2006.
  34. A. Trentham-Dietz, P. A. Newcomb, B. E. Storer, and P. L. Remington, “Risk factors for carcinoma in situ of the breast,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 7, pp. 697–703, 2000. View at Google Scholar · View at Scopus
  35. C. M. Friedenreich, C. G. Woolcott, A. McTiernan et al., “Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1458–1466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. N. F. Boyd, H. Guo, L. J. Martin et al., “Mammographic density and the risk and detection of breast cancer,” The New England Journal of Medicine, vol. 356, no. 3, pp. 227–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Lin, N. R. Cook, C. Albert et al., “Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial,” Journal of the National Cancer Institute, vol. 101, no. 1, pp. 14–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. T. W. Johnson, K. E. Anderson, D. Lazovich, and A. R. Folsom, “Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 12, pp. 1586–1591, 2002. View at Google Scholar · View at Scopus
  39. M. D. Holmes, W. Y. Chen, L. Li, E. Hertzmark, D. Spiegelman, and S. E. Hankinson, “Aspirin intake and survival after breast cancer,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1467–1472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Algra and P. M. Roth, “Effects of aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomized trial,” The Lancet Oncology, vol. 13, no. 5, pp. 518–527, 2012. View at Google Scholar
  41. N. S. Nair, N. Pandey, P.V. Vanmali et al., Journal of Clinical Oncology, vol. 29, no. 27, p. 146, 2001.
  42. R. Ruggiero, E. Procaccini, A. Sanguinetti et al., “Ductal carcinoma in situ of the breast: our experience,” Il Giornale di Chirurgia, vol. 30, no. 3, pp. 121–124, 2009. View at Google Scholar · View at Scopus
  43. H. D. Nelson, K. Tyne, A. Naik et al., “Screening for breast cancer: US preventive task force recommendation statement,” Annals of International Medicine, vol. 151, no. 10, pp. 716–726, 2009. View at Google Scholar
  44. R. E. Hendrick, E. D. Pisano, A. Averbukh et al., “Comparison of acquisition parameters and breast dose in digital mammography and screen-film mammography in the American College of Radiology imaging network digital mammographic imaging screening trial,” American Journal of Roentgenology, vol. 194, no. 2, pp. 362–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Kerlikowske, R. A. Hubbard, D. L. Miglioretti et al., “Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study,” Annals of Internal Medicine, vol. 155, no. 8, pp. 493–502, 2011. View at Google Scholar · View at Scopus
  46. C. C. Riedl, L. Ponhold, D. Flöry et al., “Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer,” Clinical Cancer Research, vol. 13, no. 20, pp. 6144–6152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. C. K. Kuhl, S. Schrading, H. B. Bieling et al., “MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study,” The Lancet, vol. 370, no. 9586, pp. 485–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. E. S. Hwang, K. Kinkel, L. J. Esserman, Y. Lu, N. Weidner, and N. M. Hylton, “Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity,” Annals of Surgical Oncology, vol. 10, no. 4, pp. 381–388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. J. H. Menell, E. A. Morris, D. D. Dershaw, A. F. Abramson, E. Brogi, and L. Liberman, “Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging,” Breast Journal, vol. 11, no. 6, pp. 382–390, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Santamaría, M. Velasco, B. Farrús, G. Zanón, and P. L. Fernández, “Preoperative MRI of pure intraductal breast carcinoma-A valuable adjunct to mammography in assessing cancer extent,” Breast, vol. 17, no. 2, pp. 186–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. A. B. Hollingsworth and R. G. Stough, “Preoperative breast MRI for locoregional staging,” The Journal of the Oklahoma State Medical Association, vol. 99, no. 10, pp. 505–515, 2006. View at Google Scholar · View at Scopus
  52. A. B. Hollingsworth, R. G. Stough, C. A. O'Dell, and C. E. Brekke, “Breast magnetic resonance imaging for preoperative locoregional staging,” American Journal of Surgery, vol. 196, no. 3, pp. 389–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Uematsu, S. Yuen, M. Kasami, and Y. Uchida, “Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 461–474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. C. D. Lehman, C. Gatsonis, C. K. Kuhl et al., “MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer,” The New England Journal of Medicine, vol. 356, no. 13, pp. 1295–1303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. J. Gwak, H. J. Kim, J. Y. Kwak et al., “Ultrasonographic detection and characterization of asymptomatic ductal carcinoma in situ with histopathologic correlation,” Acta Radiologica, vol. 52, no. 4, pp. 364–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. W. K. Moon, J. S. Myung, Y. J. Lee, I. A. Park, D. Y. Noh, and J. G. Im, “US of ductal carcinoma in situ,” Radiographics, vol. 22, no. 2, pp. 269–281, 2002. View at Google Scholar · View at Scopus
  57. M. Badruddoja and J. H. Yang, “Size of breast cancer tumor after core-needle biopsy and fine-needle aspiration does not affect patient treatment plan,” Archives of Surgery, vol. 140, no. 10, pp. 1008–1009, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Badruddoja, “Image-guided treatment of breast cancer,” Journal of the American College of Surgeons, vol. 210, no. 3, pp. 372–374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Badruddoja, “Routine preoperative MRI for breast carcinoma,” Journal of the American College of Surgeons, vol. 210, no. 2, pp. 253–255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. C. H. Lee, D. Carter, L. E. Philpotts et al., “Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?” Radiology, vol. 217, no. 2, pp. 466–470, 2000. View at Google Scholar · View at Scopus
  61. R. M. Golub, C. L. Bennett, T. Stinson, L. Venta, and M. Morrow, “Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2430–2437, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. E. Brennan, R. M. Turner, S. Ciatto et al., “Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer,” Radiology, vol. 260, no. 1, pp. 119–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. P. P. Rosen and H. Oberman, Tumors of Mammary Gland, Armed Forces Institute of Pathology, Washington, DC, USA, 1993.
  64. M. J. Silverstein, D. N. Poller, J. R. Waisman et al., “Prognostic classification of breast ductal carcinoma-in-situ,” The Lancet, vol. 345, no. 8958, pp. 1154–1157, 1995. View at Google Scholar · View at Scopus
  65. J. P. Sloane, I. Amendoeira, N. Apostolikas et al., “Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications,” Human Pathology, vol. 29, no. 10, pp. 1056–1062, 1998. View at Google Scholar · View at Scopus
  66. The Census Conference Committee, “Consensus conference of the classification of ductal carcinoma in situ,” Cancer, vol. 80, no. 9, pp. 1798–1802, 1997. View at Google Scholar
  67. D. C. Allred, “Ductal carcinoma in situ: terminology, classification, and natural history,” Journal of the National Cancer Institute. Monographs, vol. 2010, no. 41, pp. 134–138, 2010. View at Google Scholar · View at Scopus
  68. G. Cardenosa, Clinical Breast Imaging, a Patient Focused Teaching File, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2006.
  69. J. A. Chapman, N. A. Miller, H. L. Lickley et al., “Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment,” BMC Cancer, vol. 7, article 174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Rosai, “Borderline epithelial lesions of the breast,” American Journal of Surgical Pathology, vol. 15, no. 3, pp. 209–221, 1991. View at Google Scholar · View at Scopus
  71. A. Costa and V. Zanini, “Precancerous lesions of the breast,” Nature Clinical Practice Oncology, vol. 5, no. 12, pp. 700–704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Guerrieri-Gonzaga, E. Botteri, N. Rotmensz et al., “Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years,” Oncologist, vol. 14, no. 3, pp. 201–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. J. Guidi, L. Fischer, J. R. Harris, and S. J. Schnitt, “Microvessel density and distribution in ductal carcinoma in situ of the breast,” Journal of the National Cancer Institute, vol. 86, no. 8, pp. 614–619, 1994. View at Google Scholar · View at Scopus
  74. A. J. Evans, S. E. Pinder, I. O. Ellis et al., “Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression,” Clinical Radiology, vol. 49, no. 8, pp. 559–562, 1994. View at Google Scholar · View at Scopus
  75. H. J. Burstein, K. Polyak, J. S. Wong, S. C. Lester, and C. M. Kaelin, “Ductal carcinoma in situ of the breast,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1430–1441, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. D. C. Allred, G. M. Clark, R. Molina et al., “Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer,” Human Pathology, vol. 23, no. 9, pp. 974–979, 1992. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Rudas, R. Neumayer, M. F. X. Gnant, M. Mittelböck, R. Jakesz, and A. Reiner, “p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast,” European Journal of Cancer Part A, vol. 33, no. 1, pp. 39–44, 1997. View at Publisher · View at Google Scholar · View at Scopus
  78. D. J. Dabbs, M. Chivukula, G. Carter, and R. Bhargava, “Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile,” Modern Pathology, vol. 19, no. 11, pp. 1506–1511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Kasami, H. Gobbi, W. D. Dupont, J. F. Simpson, D. L. Page, and C. L. Vnencak-Jones, “Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety,” Breast, vol. 9, no. 1, pp. 23–27, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Acs, T. J. Lawton, T. R. Rebbeck, V. A. LiVolsi, and P. J. Zhang, “Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implication,” American Journal of Clinical Pathology, vol. 115, no. 1, pp. 85–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Wiechmann and H. M. Kuerer, “The molecular journey from ductal carcinoma in situ to invasive breast cancer,” Cancer, vol. 112, no. 10, pp. 2130–2142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Kerlikowske, A. M. Molinari, and M. L. Gauthier, “Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis,” Journal of the National Cancer Institute, vol. 102, no. 9, pp. 627–637, 2010. View at Google Scholar
  83. D. C. Radisky, M. Santisteban, H. K. Berman et al., “p16 INK4a expression and breast cancer risk in women with atypical hyperplasia,” Cancer Prevention Research, vol. 4, no. 12, pp. 1953–1960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. E. H. Adler, J. Sunkara, A. S. Patchefsky et al., “Predictor of disease progression in ductal carcinoma in situ of the breast and vascular pattern,” Human Pathology, vol. 43, no. 4, pp. 550–556, 2012. View at Google Scholar
  85. V. L. Ernster, J. Barclay, K. Kerlikowske, H. Wilkie, and R. Ballard-Barbash, “Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program,” Archives of Internal Medicine, vol. 160, no. 7, pp. 953–958, 2000. View at Google Scholar · View at Scopus
  86. L. G. Arnesson, S. Smeds, G. Fagerberg, and O. Grontoft, “Follow-up of two treatment modalities for ductal cancer in situ of the breast,” British Journal of Surgery, vol. 76, no. 7, pp. 672–675, 1989. View at Google Scholar · View at Scopus
  87. B. Fisher, M. Bauer, and R. Margolese, “Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer,” The New England Journal of Medicine, vol. 312, no. 11, pp. 665–673, 1985. View at Google Scholar · View at Scopus
  88. D. J. Winchester, H. R. Menck, and D. P. Winchester, “National treatment trends for ductal carcinoma in situ of the breast,” Archives of Surgery, vol. 132, no. 6, pp. 660–665, 1997. View at Google Scholar · View at Scopus
  89. E. R. Fisher, R. Sass, and B. Fisher, “Pathologic findings from the National Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DICS),” Cancer, vol. 57, no. 2, pp. 197–208, 1986. View at Google Scholar · View at Scopus
  90. A. Recht, B. S. Danoff, and L. J. Solin, “Intraductal carcinoma of the breast: results of treatment with excisional biopsy and irradiation,” Journal of Clinical Oncology, vol. 3, no. 10, pp. 1329–1343, 1985. View at Google Scholar · View at Scopus
  91. B. Fisher, J. Costantino, C. Redmond et al., “Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer,” The New England Journal of Medicine, vol. 328, no. 22, pp. 1581–1586, 1993. View at Publisher · View at Google Scholar · View at Scopus
  92. J. P. Julien, N. Bijker, I. S. Fentiman et al., “Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853,” The Lancet, vol. 355, no. 9203, pp. 528–533, 2000. View at Google Scholar · View at Scopus
  93. J. Houghton, “Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial,” The Lancet, vol. 362, no. 9378, pp. 95–102, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. B. D. Smith, B. G. Haffty, T. A. Buchholz et al., “Effectiveness of radiation therapy in older women with ductal carcinoma in situ,” Journal of the National Cancer Institute, vol. 98, no. 18, pp. 1302–1310, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Vargas, L. Kestin, N. Go et al., “Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 5, pp. 1514–1521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. E. W. L. Chuwa, V. H. S. Tan, P. H. Tan, W. S. Yong, G. H. Ho, and C. Y. Wong, “Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors,” ANZ Journal of Surgery, vol. 78, no. 1-2, pp. 42–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Wärnberg, J. Bergh, M. Zack, and L. Holmberg, “Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 5, pp. 495–499, 2001. View at Google Scholar · View at Scopus
  98. S. A. Joslyn, “Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival,” Breast Journal, vol. 12, no. 1, pp. 20–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Revesz and S. A. Khan, “What are the safe margins of resection for invasive and in situ breast cancer,” Oncology, vol. 25, no. 10, pp. 1–5, 2011. View at Google Scholar
  100. S. L. Blair, K. Thompson, J. Rococco, V. Malcarne, P. D. Beitsch, and D. W. Ollila, “Attuning negative margins in breast-conversion operation: is there a consensus among breast surgeons,” Journal of the American College of Surgeons, vol. 209, no. 5, pp. 608–613, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. I. Jiveliouk, B. Corn, M. Inbar, and O. Merimsky, “Ductal carcinoma in situ of the breast in Israeli women treated by breast-conserving surgery followed by radiation therapy,” Oncology, vol. 76, no. 1, pp. 30–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. N. Kayani and Y. Bhurgri, “Ductal carcinoma in situ (DCIS) in Karachi,” Journal of the Pakistan Medical Association, vol. 55, no. 5, pp. 199–202, 2005. View at Google Scholar · View at Scopus
  103. L. L. Hughes, M. Wang, D. L. Page et al., “Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5319–5324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. P. R. Benitez, O. Streeter, F. Vicini et al., “Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study,” American Journal of Surgery, vol. 192, no. 4, pp. 427–433, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Trombetta, T. B. Julian, D. E. Werts et al., “Long-term Cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast,” American Journal of Clinical Oncology, vol. 32, no. 3, pp. 314–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. American Association of Cancer Research, “Brachytherapy was associated with two-fold increase risk for mastectomy and complications,” American Association of Cancer Research, 2011. View at Google Scholar
  107. L. Liberman, E. A. Morris, D. D. Dershaw, A. F. Abramson, and L. K. Tan, “MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer,” American Journal of Roentgenology, vol. 180, no. 4, pp. 901–910, 2003. View at Google Scholar · View at Scopus
  108. M. Badruddoja, “Micrometastasis and axillary dissection in breast cancer,” Archives of Surgery, vol. 145, no. 10, pp. 1022–1023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. E. B. Claus, S. Petruzella, E. Matloff, and D. Carter, “Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ,” JAMA, vol. 293, no. 8, pp. 964–969, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. L. C. Hartmann, T. A. Sellers, D. J. Schaid et al., “Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers,” Journal of the National Cancer Institute, vol. 93, no. 21, pp. 1633–1637, 2001. View at Google Scholar · View at Scopus
  111. K. A. Metcalf, P. Ghadirian, B. Rosen et al., “Variation in rates of uptake of preventive options in Canadian women carrying the BRCA 1 or BRCA 2 genetic mutation,” Open Medicine, vol. 1, no. 2, pp. e92–e98, 2007. View at Google Scholar
  112. D. C. Allred, J. Bryant, S. Land et al., “Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP B-24,” Breast Cancer Research and Treatment, vol. 76, supplement 1, article S36, 2002. View at Google Scholar
  113. N. Bijker, P. Meijnen, J. L. Peterse et al., “Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853—A study by the EORTC breast cancer cooperative group and EORTC radiotherapy group,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3381–3387, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Cuzick, J. F. Forbes, I. Sestak et al., “Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial,” Journal of the National Cancer Institute, vol. 99, no. 4, pp. 272–282, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. J. L. Warren, D. L. Weaver, T. Bocklage et al., “The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population-based analysis,” Cancer, vol. 104, no. 9, pp. 1840–1848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. J. A. Cauley, L. Norton, M. E. Lippmann et al., “Continued breast risk reduction in postmenopausal women with raloxefine: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation,” Breast Cancer Research and Treatment, vol. 65, no. 2, pp. 125–134, 2001. View at Google Scholar
  117. B. A. Viring, T. Samliyan, and T. M Tuttle, “Diagnosis and management of ductal carcinoma in situ (DCIS),” Evidence Report/Technology Assessment 09-E018, AHRQ, 2009. View at Google Scholar
  118. P. E. Goss, K. Strasser-Weippl, M. Brown, R. Santen, J. Ingle, and M. Bissell, “Prevention strategies with aromatase inhibitors,” Clinical Cancer Research, vol. 10, no. 1, part 2, pp. 372S–379S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Chen, J. A. Mayer, T. I. Krisko et al., “Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells,” Cancer Research, vol. 69, no. 23, pp. 8853–8861, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Li, Y. Zhang, J. Hill et al., “The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor-negative tumors in MMTV-erbB2 mice,” Clinical Cancer Research, vol. 13, no. 20, pp. 6224–6231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. L. R. Howe, “Rexinoids and breast cancer prevention,” Clinical Cancer Research, vol. 13, no. 20, pp. 5983–5987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. D. L. Crowe and R. A. Chandraratna, “A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands,” Breast Cancer Research, vol. 6, no. 5, pp. R546–R555, 2004. View at Google Scholar · View at Scopus
  123. K. Tada, A. Ogiya, K. Kimura et al., “Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer,” World Journal of Surgical Oncology, vol. 8, article 6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Intra, N. Rotmensz, P. Veronesi et al., “Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years,” Annals of Surgery, vol. 247, no. 2, pp. 315–319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. T. B. Julian, S. R. Land, V. Fourchotte et al., “Is sentinel node biopsy necessary in conservatively treated DCIS?” Annals of Surgical Oncology, vol. 14, no. 8, pp. 2202–2208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. S. J. Katz, P. M. Lantz, N. K. Janz et al., “Patient involvement in surgery treatment decisions for breast cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5526–5533, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. S. J. Katz, P. M. Lantz, N. K. Janz et al., “Patterns and correlates of local therapy for women with ductal carcinoma-in-situ,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 3001–3007, 2005. View at Publisher · View at Google Scholar · View at Scopus